Zewei Tu

538 total citations
33 papers, 377 citations indexed

About

Zewei Tu is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Zewei Tu has authored 33 papers receiving a total of 377 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Molecular Biology, 16 papers in Pulmonary and Respiratory Medicine and 12 papers in Cancer Research. Recurrent topics in Zewei Tu's work include Ferroptosis and cancer prognosis (16 papers), Cancer-related molecular mechanisms research (9 papers) and Cancer Immunotherapy and Biomarkers (8 papers). Zewei Tu is often cited by papers focused on Ferroptosis and cancer prognosis (16 papers), Cancer-related molecular mechanisms research (9 papers) and Cancer Immunotherapy and Biomarkers (8 papers). Zewei Tu collaborates with scholars based in China and United States. Zewei Tu's co-authors include Kai Huang, Xingen Zhu, Lei Wu, Chuming Tao, Qing Hu, Jingying Li, Peng Wang, Xiaoyan Long, Xingen Zhu and Miaojing Wu and has published in prestigious journals such as Advanced Materials, Biomaterials and Frontiers in Immunology.

In The Last Decade

Zewei Tu

32 papers receiving 373 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Zewei Tu China	11	259	175	113	82	50	33	377
Hwa-Ryeon Kim South Korea	10	259 1.0×	128 0.7×	59 0.5×	92 1.1×	67 1.3×	13	381
Zeli Yin China	8	217 0.8×	199 1.1×	62 0.5×	100 1.2×	84 1.7×	11	371
Mouadh Benamar United States	9	268 1.0×	92 0.5×	85 0.8×	129 1.6×	28 0.6×	12	380
Yvonne de Jong Netherlands	13	170 0.7×	134 0.8×	181 1.6×	75 0.9×	41 0.8×	20	405
Yvonne E. Smith Ireland	9	228 0.9×	130 0.7×	140 1.2×	185 2.3×	72 1.4×	10	430
Hehui Fang China	7	229 0.9×	187 1.1×	87 0.8×	186 2.3×	36 0.7×	12	400
Robyn T. Sussman United States	11	331 1.3×	106 0.6×	61 0.5×	160 2.0×	35 0.7×	24	468
Stephen Y. Chih United States	5	178 0.7×	129 0.7×	176 1.6×	80 1.0×	108 2.2×	6	399
Yuanhao Chang China	11	250 1.0×	198 1.1×	102 0.9×	83 1.0×	115 2.3×	20	455

Countries citing papers authored by Zewei Tu

Since Specialization

Citations

This map shows the geographic impact of Zewei Tu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zewei Tu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zewei Tu more than expected).

Fields of papers citing papers by Zewei Tu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Zewei Tu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zewei Tu. The network helps show where Zewei Tu may publish in the future.

Co-authorship network of co-authors of Zewei Tu

This figure shows the co-authorship network connecting the top 25 collaborators of Zewei Tu. A scholar is included among the top collaborators of Zewei Tu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Zewei Tu. Zewei Tu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Meng, Zhouqi, Xingchun Gao, Xiangjun Tang, et al.. (2025). Signal Transducer Nanoparticles Enable Siglec‐10/G Blockade Immunotherapy for Breast Cancer Treatment. Advanced Materials. 37(39). e2502758–e2502758. 1 indexed citations

Lv, Yonghui, et al.. (2025). Mechanisms underlining R-loop biology and implications for human disease. Frontiers in Cell and Developmental Biology. 13. 1537731–1537731. 2 indexed citations

Wang, Chong, et al.. (2025). Identification of TAP2 as a novel immune target in human cancers: insights from integrated bioinformatics and experimental approaches. European journal of medical research. 30(1). 163–163. 1 indexed citations

Tu, Zewei, et al.. (2024). RUNX1-PDIA5 Axis Promotes Malignant Progression of Glioblastoma by Regulating CCAR1 Protein Expression. International Journal of Biological Sciences. 20(11). 4364–4381. 1 indexed citations

Su, Xiaoyan, et al.. (2024). DNMT3A promotes glioma growth and malignancy via TNF-α/NF-κB signaling pathway. Translational Cancer Research. 13(4). 1786–1806. 6 indexed citations

Li, Jingying, Zewei Tu, Min Luo, et al.. (2024). Endosome-microautophagy targeting chimera (eMIATAC) for targeted proteins degradation and enhance CAR-T cell anti-tumor therapy. Theranostics. 14(11). 4481–4498. 1 indexed citations

Wang, Can, et al.. (2024). Utilizing reactive oxygen species-scavenging nanoparticles for targeting oxidative stress in the treatment of ischemic stroke: A review. Open Medicine. 19(1). 20241041–20241041. 4 indexed citations

Gao, Xingchun, Xiangjun Tang, Zewei Tu, et al.. (2024). Tertiary amine modification enables triterpene nanoparticles to target the mitochondria and treat glioblastoma via pyroptosis induction. Biomaterials. 317. 123035–123035. 6 indexed citations

Tu, Zewei, Yuyang Huang, Shigang Lv, et al.. (2023). Pan-cancer analysis: predictive role of TAP1 in cancer prognosis and response to immunotherapy. BMC Cancer. 23(1). 133–133. 15 indexed citations

10.

Tu, Zewei, Xiaolin Wang, Huan Cai, et al.. (2023). The cell senescence regulator p16 is a promising cancer prognostic and immune check-point inhibitor (ICI) therapy biomarker. Aging. 15(6). 2136–2157. 5 indexed citations

11.

Tu, Zewei, et al.. (2023). Identification of a robust scoring system based on metabolic genes followed by in-depth validation of ATP1A3 in glioma. Life Sciences. 315. 121377–121377. 2 indexed citations

12.

Liu, Hao, Jie Peng, Yuguang Li, et al.. (2023). The role of lysosomal peptidases in glioma immune escape: underlying mechanisms and therapeutic strategies. Frontiers in Immunology. 14. 1154146–1154146. 6 indexed citations

13.

Tu, Zewei, Jingying Li, Xiaoyan Long, et al.. (2022). Transcriptional Patterns of Lower‐Grade Glioma Patients with Distinct Ferroptosis Levels, Immunotherapy Response, and Temozolomide Sensitivity. Oxidative Medicine and Cellular Longevity. 2022(1). 9408886–9408886. 7 indexed citations

14.

Huang, Kai, et al.. (2022). Comprehensive analysis of the prognostic and role in immune cell infiltration of MSR1 expression in lower‐grade gliomas. Cancer Medicine. 11(9). 2020–2035. 11 indexed citations

15.

Tu, Zewei, Qing Han, Xiaoyan Long, et al.. (2022). Intrinsic immune evasion patterns predict temozolomide sensitivity and immunotherapy response in lower-grade gliomas. BMC Cancer. 22(1). 973–973. 2 indexed citations

16.

Tu, Zewei, Qin Ouyang, Xiaoyan Long, et al.. (2022). Protein Disulfide-Isomerase A3 Is a Robust Prognostic Biomarker for Cancers and Predicts the Immunotherapy Response Effectively. Frontiers in Immunology. 13. 837512–837512. 29 indexed citations

17.

Tu, Zewei, Lei Wu, Jingying Li, et al.. (2021). Systematic and Multi-Omics Prognostic Analysis of Lysine Acetylation Regulators in Glioma. Frontiers in Molecular Biosciences. 8. 587516–587516. 4 indexed citations

18.

Tu, Zewei, Lei Shu, Lei Wu, et al.. (2021). A Novel Signature Constructed by RNA-Binding Protein Coding Genes to Improve Overall Survival Prediction of Glioma Patients. Frontiers in Cell and Developmental Biology. 8. 588368–588368. 18 indexed citations

19.

Tu, Zewei, Lei Wu, Peng Wang, et al.. (2020). N6-Methylandenosine-Related lncRNAs Are Potential Biomarkers for Predicting the Overall Survival of Lower-Grade Glioma Patients. Frontiers in Cell and Developmental Biology. 8. 642–642. 117 indexed citations

20.

Wang, Peng, Miaojing Wu, Zewei Tu, et al.. (2020). Identification of RNA: 5-Methylcytosine Methyltransferases-Related Signature for Predicting Prognosis in Glioma. Frontiers in Oncology. 10. 1119–1119. 30 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact